Magnetic localization systems for precise and less invasive breast cancer surgery

Endomagnetics Ltd (Endomag)

Cambridge (UK) · Munich (DE, business address Endomagnetics GmbH) · Wilmington, Delaware (US contact Hologic)New on Amplifa

2007Founded (UCL / University of Houston)

1,350+Hospitals worldwide

45+Countries on 6 continents

750,000+Patients treated

USD 310 millionAcquisition price paid by Hologic (2024)

About Endomag

Endomag is a medical technology company founded in 2007 out of research at University College London (UCL) and the University of Houston, headquartered in Cambridge, UK. The company develops and markets the Sentimag® platform for magnetic localization of tumors and lymph nodes, the Magseed® lesion marking system and the Magtrace® lymph node tracer for sentinel lymph node biopsy. These magnetic alternatives to wires and radioactive tracers are routinely used in more than 1,350 hospitals in over 45 countries; more than 750,000 patients have been treated to date. In 2024, Endomag was acquired by Hologic, a global provider in the field of women's health. For the German-speaking region, Endomagnetics GmbH with a business address in Munich (registered office in Frankfurt am Main) is registered as importer; distribution in the USA and Canada is handled by Hologic, and worldwide via distributors.

Site: CB4 0WN Cambridge
Processes: Magnetic localization of tumors and lymph nodes (Sentimag platform), Magseed lesion marking, Magtrace lymph node tracer for sentinel lymph node biopsy, Product support and training, Trial orders/evaluations
Materials: Sentimag® Platform, Magseed® Marker, Magtrace® Tracer
Founded: 2007
Industries: Medical technology, Breast cancer surgery, Oncology, Women's health

01
Research & development
02
Regulatory certification (among others EU MDR)
03
Distribution via Hologic (USA/Canada) and global distributors
04
Product support and training

Technologies

SENTIMAG

Sentimag® Platform

Surgical guidance device for magnetic detection of tumors and lymph nodes without wires and without radioactivity.

MAGSEED

Magseed® Marker

Magnetic, unbreakable seed for precise lesion marking prior to breast cancer surgery.

MAGTRACE

Magtrace® Tracer

Magnetically detectable liquid tracer for staging and sentinel lymph node biopsy.

Locations

Cambridge

Headquarters (UK Headquarters)

Munich

Business address of Endomagnetics GmbH (c/o Bird & Bird LLP)

Wilmington

US contact (Hologic, registered address)

Products

**Magseed® Marker**Magnetic lesion marking · Breast cancer surgery

**Magtrace® Tracer**Magnetic lymph node tracer · Sentinel lymph node biopsy

**Magseed® Pro**Advanced marker · Lesion localization

Inside the production

Industries

Medical technologyBreast cancer surgeryOncologyWomen's health

Additional services

Magnetic localization of tumors and lymph nodes (Sentimag platform)Magseed lesion markingMagtrace lymph node tracer for sentinel lymph node biopsyProduct support and trainingTrial orders/evaluations

Reference customers

MD Anderson Cancer CenterUniversity of California San FranciscoSutter HealthVanderbiltDana-Farber Cancer InstituteInova Schar Cancer InstituteCompass OncologyBaptist Health PaducahSt Stephen's Hospital Hervey BayRoyal Bolton HospitalBaystate Noble HospitalOhioHealth1,350+ hospitals worldwide

History

2007
Founded out of research at University College London (UCL) and the University of Houston
2018
The Queen's Award for Enterprise – Innovation
2021
Queen's Award for Enterprise International Trade; Financial Times Europe's Fastest Growing Companies; Prix Galien USA Shortlist
2024
King's Award for Enterprise International Trade; acquisition by Hologic for USD 310 million (completed July 2024)
2026
Hologic itself was acquired by Blackstone and TPG for USD 18.3 billion